Research programme: monoclonal antibody conjugates - Stemline Therapeutics

Drug Profile

Research programme: monoclonal antibody conjugates - Stemline Therapeutics

Alternative Names: SL-101; SL-601

Latest Information Update: 15 Dec 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Stemline Therapeutics
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies

Most Recent Events

  • 12 Nov 2014 Stemline has patent protection for monoclonal antibody conjugates in USA
  • 14 Aug 2014 Preclinical development of SL 101 is ongoing in USA
  • 10 Dec 2012 Preclinical trials in Haematological-malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top